Drug intelligence / Profile preview

apatinib + camrelizumab + fuzuloparib

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A triplet combination therapy consisting of apatinib (a VEGFR-2 inhibitor), camrelizumab (an anti-PD-1 antibody), and fuzuloparib (a PARP inhibitor). This combination leverages synergistic effects between anti-angiogenesis, immune checkpoint inhibition, and PARP inhibition pathways to target cancer cells through multiple mechanisms. Clinical studies have shown promising efficacy in platinum-resistant recurrent ovarian cancer and triple-negative breast cancer with manageable toxicity profiles.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on apatinib + camrelizumab + fuzuloparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apatinib + camrelizumab + fuzuloparib.

Explore the full profile